Mergers & Acquisitions ·
Aethlon Medical, Inc. entered into a definitive merger agreement with North Immunology, Inc., an all-stock transaction…
AEMDAethlon Medical Inc
Aethlon Medical, Inc. entered into a definitive merger agreement with North Immunology, Inc., an all-stock transaction where North Immunology will become a wholly owned subsidiary before merging into Aethlon's surviving entity. The combined company will operate as North Immunology, Inc., trading on Nasdaq under the ticker NRTX, with pre-merger North Immunology stockholders expected to own approximately 95.25% of the new entity and Aethlon shareholders retaining about 4.75%. Concurrently, a $180 million oversubscribed private placement (PIPE) is closing immediately prior to the merger, consisting of $146 million in cash and $34 million from convertible notes, providing capital through the second half of 2028. Aethlon shareholders will receive one contingent value right per share, entitling them to proceeds from any future monetization of Aethlon's legacy Hemopurifier assets. The transaction is expected to close in Q1 2027, subject to stockholder and regulatory approvals. Aethlon Medical operates as a medical therapeutic company developing immunotherapeutic devices for cancer and viral diseases.